James P. Corsetti, M.D., Ph.D.

James P. Corsetti, M.D., Ph.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 608
Rochester, NY 14642

Office: (585) 275-4907
Fax: (585) 273-3003

Research Bio

My current research interests focus on studies of cardiovascular disease risk in human populations using non-traditional statistical approaches, especially as related to risk associations involving novel biomarkers as well as genetic markers. Underlying our approach is the hypothesis that particular blood and genetic risk markers are most efficacious in particular patient subgroups and that, in general, different patient subgroups have different markers of risk. As such, we have recently developed a 3-dimensional graphical exploratory data analysis technique that we call "outcome event mapping"

that allows identification of high-risk patient subgroups not constrained by traditional rectilinear approaches to subgroup identification and allowing subgroup identification even in unexpected regions of risk parameter domains. With it, we have demonstrated a high-risk subgroup in post-MI patients based upon high levels of serum C-reactive protein (CRP) and total cholesterol. Interestingly, we have shown the counter-intuitive result that within this subgroup elevated high-density lipoprotein (HDL) cholesterol, the so-called "good cholesterol", is a risk factor for recurrent events, a finding that we ascribe to transformation of the usual anti-inflammatory HDL into pro-inflammatory HDL. We have also been able to adapt outcome event mapping to delineate subgroup-specific risk in association with single-nucleotide polymorphism (SNP) variants. For example, we have shown that a variant of a SNP in the p22phox subunit of NAD(P)H oxidase (an enzyme playing a critical role in generation of reactive oxygen species and thus potentially in the transformation of HDL) is associated with risk along with elevated HDL in this subgroup. We plan future studies to delineate mechanisms involved in elevated HDL-associated risk using outcome event mapping with additional genetic markers together with advanced statistical techniques to elucidate causal pathways; and to fully characterize the physico-chemical nature of changes at the molecular level in HDL mediating transformation of HDL from anti-inflammatory to pro-inflammatory in nature.

Awards & Honors (Local)

Member, Who's Who in Science and Engineering 2000 - Present


Serum Glocose and Triglyceride Determine High-Risk Subgroups in Non-diabetic Postinfarction Patients

United States Serial NO.: 11/809,832
Filed Date: May 31, 2007
Title: Identifying Risk of a Medical Event
Invented by: James Corsetti, Charles Sparks, Daniel Ryan, Arthur Moss

Recent Journal Articles

Showing the 5 most recent journal articles. 33 available »

2016 Sep
Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE. "Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling." Data in brief. 2016 Sep; 8:98-104. Epub 2016 May 21.
2016 Jul
Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE. "Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation." Atherosclerosis. 2016 Jul; 250:1-8. Epub 2016 Apr 21.
Corsetti JP, Gansevoort RT, Bakker SJ, Dullaart RP. "Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study." Journal of clinical lipidology. 2016 10(4):842-50. Epub 2016 Mar 12.
2014 Dec
Corsetti JP, Gansevoort RT, Bakker SJ, Sparks CE, Vart P, Dullaart RP. "Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants." Journal of the American Society of Nephrology : JASN. 2014 Dec; 25(12):2906-15. Epub 2014 May 22.
2014 Jun
Sparks CE, Corsetti JP, Sparks JD. "High-density lipoproteins: taking the good with the bad." Current opinion in lipidology. 2014 Jun; 25(3):230-2.

Current Appointments

Director, Strong West Lab - Department of Pathology and Laboratory Medicine (SMD)
Medical Director, URMC Clinical Trials Center - Department of Pathology and Laboratory Medicine (SMD)
Professor - Department of Pathology and Laboratory Medicine (SMD) - Primary


Clinical Pathology/Laboratory Medicine - American Board of Pathology
Anatomic Pathology and Clinical Pathology - American Board of Pathology


MD | Medicine | Brown Univ Bio/Med Sciences1982
PhD | Physical Chemistry | Harvard University1980
MA | Physical Chemistry | Harvard University1971
BS | Chemistry | Univ Rhode Island1969

Post-Doctoral Training & Residency

Residency in Pathology at University of Rochester Medical Center06/01/1985 - 06/30/1986
Residency in Pathology at University of Rochester Medical Center07/01/1982 - 06/30/1986